Rein Therapeutics, Inc. Restructuring Charges
Rein Therapeutics, Inc. (RNTX) reported Restructuring Charges of $0 for the 12-month period ending 2024-12-31, per its 10-K filed 2025-04-07.
Financial Statements › Expense Statement › Operating Expenses
us-gaap:RestructuringCharges · last filed 2025-04-07
- Rein Therapeutics, Inc. restructuring charges for the quarter ending 2024-12-31 was $0.00.
- Rein Therapeutics, Inc. restructuring charges for the quarter ending 2024-09-30 was $0.00, a 100.00% decline year-over-year.
- Rein Therapeutics, Inc. restructuring charges for the quarter ending 2024-06-30 was $0.00.
- Rein Therapeutics, Inc. restructuring charges for the quarter ending 2024-03-31 was $0.00, a 100.00% decline year-over-year.
- Rein Therapeutics, Inc. restructuring charges for fiscal 2024 was $0.00, a 100.00% decline from fiscal 2023.
- Rein Therapeutics, Inc. restructuring charges for fiscal 2023 was $928.00K.
| Period end | Restructuring Charges 3 month | Restructuring Charges 6 month | Restructuring Charges 9 month | Restructuring Charges 12 month |
|---|---|---|---|---|
| 2024-12-31 | $0.00 derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | $0.00 derived: sum of 2 quarters · filed 2025-04-07 | $0.00 derived: sum of 3 quarters · filed 2025-04-07 | $0.00 10-K · filed 2025-04-07 |
| 2024-09-30 | $0.00 10-Q · filed 2024-11-14 | $0.00 derived: sum of 2 quarters · filed 2024-11-14 | $0.00 10-Q · filed 2024-11-14 | -$12.00K derived: sum of 4 quarters · filed 2025-04-07 |
| 2024-06-30 | $0.00 10-Q · filed 2024-08-14 | $0.00 10-Q · filed 2024-08-14 | -$12.00K derived: sum of 3 quarters · filed 2025-04-07 | -$6.00K derived: sum of 4 quarters · filed 2025-04-07 |
| 2024-03-31 | $0.00 10-Q · filed 2024-05-15 | -$12.00K derived: sum of 2 quarters · filed 2025-04-07 | -$6.00K derived: sum of 3 quarters · filed 2025-04-07 | -$94.00K derived: sum of 4 quarters · filed 2025-04-07 |
| 2023-12-31 | -$12.00K derived: 10-K 12 month − 10-Q 9 month · filed 2025-04-07 | -$6.00K derived: sum of 2 quarters · filed 2025-04-07 | -$94.00K derived: sum of 3 quarters · filed 2025-04-07 | $928.00K 10-K · filed 2025-04-07 |
| 2023-09-30 | $6.00K 10-Q · filed 2024-11-14 | -$82.00K derived: sum of 2 quarters · filed 2024-11-14 | $940.00K 10-Q · filed 2024-11-14 | |
| 2023-06-30 | -$88.00K 10-Q · filed 2024-08-14 | $934.00K 10-Q · filed 2024-08-14 | ||
| 2023-03-31 | $1.02M 10-Q · filed 2024-05-15 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| HYPERION DEFI, INC. (HYPD) | United States | $0.065B | |
| XBiotech Inc. (XBIT) | United States | $0.066B | -1.56 |
| Skye Bioscience, Inc. (SKYE) | United States | $0.061B | -0.48 |
| CalciMedica, Inc. (CALC) | United States | $0.061B | -1.42 |
| TALPHERA, INC. (TLPH) | United States | $0.060B | |
| Boundless Bio, Inc. (BOLD) | United States | $0.059B | -0.88 |
| NOMAD POWER SOLUTIONS, INC. (NMAD) | United States | $0.058B | |
| Connect Biopharma Holdings Ltd (CNTB) | $0.069B | -2.17 | |
| Yarrow Bioscience, Inc. (YARW) | United States | $0.070B | |
| Annovis Bio, Inc. (ANVS) | United States | $0.056B | -1.58 |